Research programme: cancer therapeutics - Echelon Biosciences/AMRI Hungary
Latest Information Update: 27 Aug 2009
Price :
$50 *
At a glance
- Originator AMRI Hungary; Echelon Biosciences
- Class Small molecules
- Mechanism of Action Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 May 2007 Albany Molecular Research is now called AMRI
- 02 Feb 2005 Echelon Biosciences has acquired the rights to all intellectual property associated with its collaboration with ComGenex
- 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris